© 2022 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
November 25, 2022
Closing out their discussion on the management of blastic plasmacytoid dendritic cell neoplasm, expert panelists look toward the future treatment paradigm.
Shared insight on a number of novel therapies and treatment modalities being investigated in patients with blastic plasmacytoid dendritic cell neoplasm.
November 18, 2022
Comprehensive insight on the sequencing of agents in BPDCN management, followed by considerations for use of stem cell transplant in this setting.
Centering discussion on the third patient case, panelists review second-line therapy options for those who relapse with blastic plasmacytoid dendritic cell neoplasm.
November 11, 2022
Expert panelists review the case of a 22-year-old woman diagnosed with BPDCN and consider the role of first-line chemotherapy in this setting.
Closing out their discussion on the first patient case of BPDCN, panelists consider which factors best inform the optimal selection of frontline therapy.